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ABSTRACT  
Short-term ventricular assist devices (VADs) are mechanical pumps that are used to 
temporarily support a patient who is in cardiogenic shock. These VADs are effective in 
sustaining a patient’s life until he or she can been transferred to a tertiary cardiac center 
such as the University of Michigan Health System. The researcher examined patients’ 
clinical status at the time of transfer and used univariate analysis to determine which 
factors are likely to predict a successful outcome. Multivariate analysis showed that 
younger age and better kidney function were prognostic variables in the patients’ 30-day 
and long-term survival. These factors improve the chances of a patient becoming a heart 
transplant candidate and increase the probability of long-term survival.  
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CHAPTER 1: Introduction  
Introduction  
 Almost 80 million American adults have some form of heart disease, also known as 
cardiovascular disease (CVD). Many of these patients can be treated with medications and 
lifestyle changes, while others are prone to heart attacks, cardiogenic shock, and heart failure. 
Often the only hope of recovery for someone with severe heart failure is heart transplantation or 
ventricular assist device (VAD) therapy.  However, many hospitals in the United States are not 
equipped to handle such operations or care for these patients. Therefore, many patients are not 
located near a major cardiac center when their disease progresses or when they are in an 
emergency situation.  Physicians at smaller hospitals will often use a short-term VAD to stabilize 
patients until they can be transported to a tertiary medical center for further treatment.  Relatively 
few studies have reported on the long-term outcomes of patients supported on short-term VADs 
and transferred to a tertiary center. Significantly more data are needed to determine whether 
patient selection and improvements in clinical management can improve survival for these 
patients. Identification of clinical variables prognostic in patient outcome could be invaluable to 
physicians not only at the tertiary centers but the referring hospitals as well. This study is an 
analysis of patients transferred to the University of Michigan Health System (UMHS) on a short-
term ventricular assist device from 1997 – 2007.  
Background 
 The heart functions to pump blood to all parts of the body so that oxygen can reach all of 
the cells, but there are many diseases and conditions that cause the heart to perform inadequately. 
The American Heart Association reports that cardiovascular disease is the leading cause of death 
in the United States, resulting in nearly 2400 deaths every day (2007).  There are numerous 
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forms of CVD including hypertension, coronary heart disease, heart failure, and stroke. 
Sometimes these conditions can develop slowly over time and are influenced by genetics as well 
as environment. Other forms of CVD can develop more rapidly, such as viral cardiomyopathy or 
myocardial infarction. 
 Many people with heart disease are able to keep their condition under control with 
medications and lifestyle changes, such as diet modification and exercise. However, often the 
condition progresses and a patient may require a more invasive procedure, such as percutaneous 
coronary interventions (PCIs). PCIs include treatments such as angioplasty or stents, which are 
performed to open narrow or blocked arteries.  Sometimes even PCI is not enough and surgery is 
required. One of the most common heart surgeries is coronary artery bypass grafting (CABG), 
which involves bypassing clogged arteries with another vessel.  
 Sometimes heart disease may progress into heart failure, a condition in which the heart 
fails to function properly. This can occur suddenly as a result of a myocardial infarction resulting 
in cardiogenic shock or can progress in a chronic fashion as a result of an underlying CVD.  
 Another cause of heart failure occurs when a patient fails to recover adequate heart 
function after being on cardiopulmonary bypass during a cardiac operation. This specific 
circumstance is called postcardiotomy heart failure. Treatment for heart failure, whatever the 
cause, may include surgery, implantation of mechanical assist devices, or heart transplantation.  
There are more 2200 heart transplants performed each year in the United States; it is the 
fourth most common organ transplanted behind corneal, kidney, and liver transplants (U.S. 
National Library of Medicine and National Institutes of Health, 2006).  There are many people 
on the waiting list for a heart transplant, but often a heart never becomes available due to the 
shortage of donor organs. Therefore, many physicians and patients have begun looking for 
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alternatives and other therapies to help patients either “hold on” long enough to wait for a heart 
or to help their heart recover in the hopes of not needing a heart transplant at all. One such 
therapy is the implantation of a VAD. 
 VADs are mechanical pumps that assist the heart in pumping blood when it is unable to 
do so due to heart failure. There are many different types and uses of VADs. Some are 
considered temporary and meant for shorter support times of hours or days. Other VADs are 
designed for long-term use and may be used for cardiogenic support for months or years. One 
common use of long-term VAD is for cardiogenic support while a patient is awaiting heart 
transplantation. An example of a temporary VAD is shown in Figure 1. It consists of an external 
device that is powered by a pneumatic console and is designed to support one or both of the 
ventricles for a short period of time. 
 
Figure 1. – Abiomed BVS5000; a temporary assist device 
 One major limitation of VAD and heart transplant therapy is that only a limited number 
of medical centers are able to provide this treatment. For a patient in a life-threatening situation 
and at a medical facility without these capabilities, there are typically few options available to 
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them. Short-term VADs have become more readily available at smaller facilities and are a 
feasible treatment for patients in cardiogenic shock. These VADs are designed to support 
patients until they can be transferred to a tertiary cardiac center for further treatment, which may 
involve recovery, implantation of a long-term VAD, or heart transplantation. This system of 
patient transfer is often referred to as a “hub and spoke,” with the tertiary center as the hub 
receiving patients from the referring “spoke” hospitals. As more mechanical circulatory support 
devices are developed and studied, more centers will be able to report their success with this 
treatment, allowing physicians at both large and small hospitals to use the knowledge to better 
manage their heart failure patients. 
Study Objective 
 The objective of this study is to identify prognostic variables based on patient 
information available within the first 24 hours of transfer to the University of Michigan Health 
System that may improve patient care and outcomes.  
Study Goal 
 Suggesting prognostic variables to make patient care decisions to improve outcomes with 
short-term mechanical circulatory support is the goal of this research. 
Hypothesis 
 Clinical characteristics of the patient’s status within the first 24 hours of presentation 
with temporary VADs have significant prognostic value with respect to short- and long-term 
survival. 
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CHAPTER 2: Review of Literature 
 Mechanical pumps are becoming more common in the treatment of heart failure and 
cardiogenic shock. They are the subject of many clinical trials, most of which are designed to 
study the safety and effectiveness with the newer generations of VADs. Only a few centers have 
published their experiences of patients who are transferred to their institution from the referring 
hospital, commonly referred to as the “hub and spoke system.” 
 Helman et al. (1999) published findings from Columbia-Presbyterian Medical Center 
after they established a referral network for patients who were potentially in need of a long-term 
VAD. They reported on 44 postcardiotomy patients, all of whom were being supported by a 
short-term VAD or other cardiogenic support therapies given at an outside hospital. They 
reported that 66% of the patients survived to discharge and that utilization of referral networks 
may substantially improve survival rates for postcardiotomy heart failure patients.   
 Years later, Kherani et al. (2003) reported further success of the hub and spoke system at 
Columbia-Presbyterian Medical Center. They performed a retrospective review of 46 patients 
with acute cardiogenic shock who had been transferred to their facility for further treatment. All 
patients received a long-term VAD for treatment, and their survival to discharge rate was 57%. 
This study also analyzed organ function tests as possible predictors to survival, although none 
were shown to be significant in this study. Not all patients in their study received a VAD at the 
spoke hospital, but it concluded that patients in cardiogenic shock may have better outcomes 
after referral to a large center. 
 R. J. Morris et al. (2005) conducted a prospective study of VAD supported patients at the 
University of Pennsylvania Hospital from 1997 to 2000. They separated their subjects into two 
cohorts: those who received a VAD at their institution (n= 76) or those who were transferred 
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from another hospital with a VAD already implanted for cardiac support (n=28). Analysis of 
their transferred patients showed a survival rate of 32%. All of these survivors went on to receive 
a heart transplant. This study differs from the Columbia experiences because they focused on 
only patients with VAD support. However, this study did not have many patients who were 
transferred to their hospital and also did not look at long-term survival.  
 Another study published by Gonzalez-Stawinski et al. (2006) examined the regional 
referral system for patients who were transferred to the Cleveland Clinic Foundation with an 
acute mechanical support device.  This study reported the outcomes and variables that could 
influence survival of these patients. Thirty-nine patients were studied in a retrospective review 
from 1995-2003. The majority (85%) of the transferred patients were on VAD support, but the 
study also included patients who arrived on other types of cardiogenic support. Their survival 
rate was calculated to be 38%.  Almost half were able to be weaned from support, while the 
others received long-term VAD support and/or heart transplantation. They concluded that 
patients who had undergone less complex surgical procedures were more likely to survive.  
 This study seeks to expand our knowledge of patient outcomes after transfer to a tertiary 
cardiac center with a short-term VAD for cardiogenic support. Examining patients’ clinical 
status upon arrival and examining their survival may identify variables that are important in 
predicting survival for future patients. Most of the previous studies have not reported on the 
long-term outcomes of these patients, nor did they look at specific clinical variables such as 
laboratory tests, hemodynamics, and medications upon arrival. 
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CHAPTER 3: Research Design and Methodology 
Study Design 
 This analysis is a single-center retrospective study of patients transferred to UMHS with 
a VAD for short-term cardiogenic support.  The study was approved by the Eastern Michigan 
University Human Subjects Committee and the University of Michigan’s IRBMED prior to data 
collection.  A waiver of consent was granted for this study.  
Study Population  
 Patients satisfying the study inclusion criteria were identified under the guidance of 
UMHS faculty advisor Francis D. Pagani, MD, PhD, Associate Professor of Surgery in the 
Section of Cardiac Surgery.  
Inclusion/Exclusion Criteria 
 Subjects were included in this study if they were transferred to UMHS from an outside 
hospital after implantation of a short-term cardiac assist device for cardiogenic support. No age 
or other physiological limitation was established. 
 Patients on extracorporeal-membrane oxygenation (ECMO) were excluded from this 
study in order to maintain homogeneity of the subject population by eliminating patients who 
may be in respiratory failure. 
Data Collection 
 Medical records were obtained for all subjects from the UMHS Health Information 
Management Department and the CareWeb system of electronic records at UMHS. Outside 
hospital records were reviewed only if they were already part of the patient’s medical record at 
UMHS.  Intensive Care Unit (ICU) critical care sheets were reviewed for the patients’ first 24 
hours at UMHS in order to determine their clinical status at the time of transfer. Variables that 
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were captured included, but were not limited to, demographics, medical history, outside hospital 
information, clinical status upon transfer, laboratory test results, and hospitalization times. 
 Patient outcomes were ascertained by review of current medical records or collection of a 
death certificate. Patients who had not been seen by a UMHS healthcare member since their 
discharge and did not have current information in their medical records were considered alive if 
they were not identified in the Social Security Death Index.   
Data Analysis  
 SPSS (SPSS Inc, Version 15.0) and Microsoft Excel were utilized for Data Analysis. 
Statistical analysis included examining overall study population characteristics using 
mean+standard deviation and proportions. Survival estimates were performed using Kaplan-
Meier analysis. Univariable analysis of dichotomous variables was performed using a chi-square 
test. Continuous variables were subjected to univariable analysis by utilizing an independent t-
test. Level of significance for inclusion into a multivariable model was defined at p<0.05.  
Multivariable analysis was performed by a Cox regression method importing values identified as 
significant by univariable analysis.  Comparison of survival estimates was done by log rank 
analysis.  
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CHAPTER 4: Results and Data Analysis 
Study Population 
 Forty-eight patients with a temporary VAD implanted for heart failure at an outside 
hospital and transferred to the University of Michigan Health System for further care were the 
subject of this analysis. All transfers occurred between September of 1997 and June of 2007. The 
age range of all patients was 14-77 years and the median age was 50.9 years. Figure 2 shows the 
age distribution of the population.   
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Figure 2. Age distribution. 
 
 The majority of these patients were Caucasian males in their late forties with ischemic 
heart disease and a history of hypertension and myocardial infarction (see Table 1). Analysis of 
their medical history showed that 60% of these patients did not have any cardiac procedures 
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prior to their implant, while those who had Coronary Artery Bypass Graft (CABG) surgery or 
percutaneous coronary interventions (PCI) were 15% and 25%, respectively. 
Table 1 
Demographics and Medical History 
Variable Overall No. (%) 
Mean age (years)a 49.6 +/- 12.9 
Range 14.8 – 77.3 
Gender  
Male (%) 31 (65%) 
Female (%) 17 (35%) 
Race  
Caucasian (%) 39 (81%) 
African American (%) 3 (6%) 
Unknown (%) 6 (13%) 
Body surface area (M2)a 2.01 +/- 0.24 
Body Mass Index 28.99 +/- 4.97 
Co-morbidities  
Hypertension (%) 30 (63%) 
Diabetes (%) 18 (38%) 
COPD (%) 3 (6%) 
Myocardial infarction (%) 35 (73%) 
Etiology  
Ischemic (%) 40 (83%) 
Nonischemic (%) 8 (17%) 
Prior cardiac procedures  
None (%) 29 (60%) 
PCI/PTCAb (%) 12 (25%) 
CABGc (%) 7 (15%) 
aMean +/- Standard Deviation.  
bPCI/PTCA = Percutaneous Coronary Interventions / Percutaneous Coronary Angioplasty 
cCABG = Coronary Artery Bypass Graft 
 
Implant Information 
 All patients presented to an outside hospital for either emergency service or routine care. 
During their visit they developed heart failure, and a temporary VAD was implanted for support. 
Table 2 shows that the majority of patients came from a large hospital.  Experience and 
sophistication of medical care at the referring hospital was arbitrarily defined by the number of 
cardiac surgical procedures performed yearly at the referring institution.  All hospitals were 
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located in Michigan or northwest Ohio and frequently refer patients to UMHS, which performs 
more than 800 cardiac procedures per year and is a regional transplant center.  
Table 2 
Information on Implant and Referring Hospital 
Variable Overall No. (%) 
Referral Hospitala  
Small (0-200) 1 (2%) 
Medium (201-500) 19 (40%) 
Large (501+) 27 (56%) 
Unknown 1 (2%) 
Indication  
Cardiogenic Shock 11 (23%) 
Postcardiotomyb 37 (77%) 
Post-CABG 34 (71%) 
Acute MI (< 7 days) 26 (54%) 
Type of support  
Left (LVAD) only 18 (38%) 
Right (RVAD) only 2 (4%) 
Both (BiVAD) 28 (58%) 
Specific Device  
ABIOMED BVS5000 46 (96%) 
BioMedicus 2 (4%) 
Days from Admission to Implantc 2.06 +/- 2.3 
Days from Implant to Transferc 2.1 +/- 3.4 
aBased on number of cardiac procedures performed annually (in parentheses). 
bImplantation occurring ≤ 24 hours after cardiac surgery. 
cMean +/- Standard Deviation 
 
 More than three-fourths of the patients required a VAD for postcardiotomy, which was 
defined as heart failure occurring within 24 hours of cardiac surgery.  The majority of 
postcardiotomy patients were undergoing CABG surgery as treatment for their heart disease at 
the time of VAD implantation. More than one-half of all study patients were diagnosed as having 
had a heart attack within the seven days prior to receiving their implant.  
 Temporary VADs can be used to support either one of the ventricles or both ventricles 
depending on the severity of the heart failure. Most patients required biventricular support 
(BiVAD), meaning that two devices were implanted. The ABIOMED BVS5000 (ABIOMED, 
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Inc, Danvers, MA) is a popular device used in small hospitals to support patients in cardiogenic 
shock (see Figure 1). All but two of the patients transferred to UMHS were being supported by 
the ABIOMED BVS5000. 
Clinical Status upon Presentation to UMHS 
 In order to identify variables that may be prognostic of survival, it was important to 
investigate the condition of a patient upon arrival from the referring hospital. Data were collected 
as close to transfer as possible. Table 3 shows the overall characteristics of this population 
including vital signs, hemodynamics, pump parameters, medication requirements, and other 
clinical factors.  
 The results show that every patient was in need of ventilator support (100%). Data on 
ventilator mode and rate were collected as well as PEEP and FiO2 requirements. Intra-aortic 
balloon pumps (IABP) are devices placed in the aorta that increase blood flow to the heart. They 
are often used alone but may be used in combination with a VAD. One-fourth of the patients in 
this study arrived with an IABP in place. 
 Organ failure is a common risk of heart failure. When the kidneys are not functioning 
properly, dialysis is required. One type of dialysis used in these situations is continuous veno-
venous hemofiltration (CVVH). Analysis showed that 23% of these patients required CVVH 
within the first 24 hours of presentation to UMHS. 
 Medication requirements upon arrival were collected from each patient’s ICU flow sheet.  
Three categories of medications were used in this analysis. Inotrope medications help the heart 
beat stronger when it is incapable of doing so on its own. Vasoconstrictors contract the smooth 
muscle in blood vessels, causing them to constrict and restrict blood flow. Vasodilators  
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Table 3 
Patient Status upon Arrival at UMHS 
Variable Value 
Vital Signs/Hemodynamics  
Heart Rate (bpm) 89.0 +/- 22 
Mean Systolic Blood Pressure 86.1 +/- 21 
Temperaturea (C)  37.2 +/- 0.8  
Pulmonary Artery Pressure 28.3 +/- 11 
Central Venous Pressure 18.7 +/- 8 
Cardiac Output 4.9 +/- 1.1 
LVAD flow  (L/min) 4.6 +/- 0.7 
RVAD flow  (L/min) 4.6 +/- 0.9 
Heart Rhythm  
Sinus 32 (67%) 
Paced 8 (17%) 
Atrial fibrillation 3 (6%) 
Ventricular fibrillation 1 (2%) 
Arterial Blood Gases  
O2 Saturation (%) 93.4 +/- 6.1 
pO2 143.4 +/- 111 
pCO2 36.8 +/- 7.5 
pH 7.41 +/- 0.1 
Ventricular Support Required 48 (100%) 
Ventilator Rate  (breaths/min) 13.65 +/- 3.7 
Ventilator Mode  
AC 20 (41.7%) 
IMV 26 (54.2%) 
PEEP  (cmH2O) 6.47 +/- 2.3 
FiO2 (%) 87.5 +/- 20.6 
Intra-aortic Balloon Pump (IABP) 12 (25%) 
Medication requirements  
Inotropes 28 (58.3%) 
Vasoconstrictors 25 (52.1%) 
Vasodilators 12 (25.0%) 
Chest tube output (mL)b  537 +/- 483 
Urine output (mL)b 1207 +/- 1276 
Dialysis (CVVH)c 11 (22.9%) 
aTmax over first 24 hours.  
bOver first 8 hours at UMHS. 
cWithin first 24 hours at UMHS. 
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act by opening blood vessels, which allows for more blood flow. More than half of the patients 
were on inotropic and/or vasoconstrictor support, while only 25% were on vasodilator support. 
 In addition to these clinical characteristics, laboratory values upon arrival were also 
explored. Those studied were chemistry panels, liver function tests, hematology, and 
coagulation. These tests are routinely done when a patient is brought to the hospital. Table 4 
shows the mean, standard deviation, median, and range for the patient population. 
Table 4 
Laboratory Values upon Transfer to UMHS 
Test Mean SD Median Range 
Chemistry Panel     
Sodium (mMOL/L) 140.5 6.31 141.5 128 - 156 
Potassium (mMOL/L) 4.29 0.813 4.2 2.4 - 6.5 
Chloride (mMOL/L) 108.3 5.86 108.5 93 - 121 
Bicarbonate (mMOL/L) 25.42 3.6 26.0 18 - 33 
Urea Nitrogen (mg/dL) 25.6 12.23 23.0 8 - 60 
Creatinine (mg/dL) 1.67 0.88 1.4 0.4 - 4 
Glucose (mg/dL) 145.4 56.2 141.5 71 - 367 
Calcium (mg/dL) 7.35 0.96 7.4 5.6 - 9.6 
Phosphorus (mg/dL) 4.53 2.17 4.0 1.6 - 14.5 
Protein – total (g/dL) 4.25 0.8 4.3 2.5 - 5.9 
Liver Function     
Albumin (g/dL) 2.09 0.51 2.0 1.2 - 3.5 
Aspartate Amino Transferase (IU/L) 1007 1592.8 379.0 25 - 7132 
Alanine Amino Transferase  (IU/L) 365.3 646.8 89.0 20 - 2797 
Lactic Acid Dehydrogenase (IU/L) 1884.8 2307 936.5 292 - 8994 
Alkaline phosphatase (IU/L) 66.62 52.11 50.0 25 - 322 
Total Bilirubin (mg/dL) 2.21 2.41 1.2 0.4 -12.1 
Hematology     
White Blood Cell Count (K/MM3) 11.79 4.89 11.5 0.9 - 22.9 
Hematocrit (%) 32.24 4.57 31.9 22.8 - 46.6 
Hemoglobin (g/dL) 11.18 1.51 10.9 7.9 - 15.9 
Platelet Count (K/MM3) 104.6 49.25 97.0 31 - 231 
Coagulation     
Prothrombin Time (sec) 15.7 13.5 12.3 10 - 100 
International Normalized Ratio 1.56 1.4 1.2 0.9 - 10.1 
Partial Thromboplastin Time (sec) 63.18 29.62 53.7 23.4 - 100 
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Overall Survival 
 Data captured from patient demographics, medical history, implant information, and 
clinical condition upon arrival all provide a clearer understanding of the condition in which these 
patients arrived for further care at UMHS.  
 After analysis of the patient’s clinical condition, overall survival was examined.  Twenty-
eight of the patients had their deaths confirmed by the medical records. Thirteen patients were 
currently under the care of a UMHS physician and considered alive. The remaining seven 
patients were searched for in the Social Security Death Index. This national database was 
evaluated by Cowper, Kubal, Maynard, and Hayes (2002) and found to be a reputable source for 
researching morality. Two patients were listed as expiring. The remaining five patients were 
considered to be alive as of September 2007 and considered alive for data analysis. Median 
duration of follow-up for all patients was 18 days and survival to discharge from UMHS was 
calculated as 46%.  
 Figure 3 shows the Kaplan-Meier analysis of survival for all 48 patients following their 
temporary VAD implant. The analysis shows that the population appears to be divided into two 
roughly equal groups: those who die very soon after implant account for 54% of the population, 
and those who go on to live past 30 days after implant account for 46%.   
 The next step in the data analysis was to determine if any variables were significant 
between these two groups.  
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Figure 3. Kaplan-Meier plot of survival in all patients. 
 
Identification of Prognostic Variables of Survival at 30 Days Post-Implant 
 Univariable analysis was performed on all data points to determine which variables 
should be incorporated into a multivariable analysis to identify those factors prognostic of a 
patient’s survival after implant. The population was separated into two groups for comparison: 
those who survived 30 days after implant of their temporary VAD (N=22) and those patients 
who expired prior to 30 days (N=26). 
 Table 5 shows the univariate analysis results of demographics and medical history.  Age 
at the time of implant (p= 0.001) and a history of diabetes (p=0.000) were shown to be 
significant. 
  16
Table 5 
Univariable Analysis of Demographics and Medical History for Those Surviving  
30 Days Post Implant.  
 30 Days Post Implant  
Variable Survivors Nonsurvivors p 
Mean age (years)a 43.2+/-12.6 55.1 +/- 10.5 0.001 
Gender    
Male 12 19 0.232 
Female 10 7  
Race   0.258 
Caucasian 19 20  
African American 2 1  
Unknown 1 5  
Body Surface Area (M2)a 1.96 +/- 0.23 2.06 +/- 0.25 0.167 
Body Mass Index (kg/m2)b  27.95 +/- 4.68 29.86 +/- 5.12 0.186 
Co-morbidities    
Hypertension 13 17 0.768 
Diabetes 2 16 0.0001 
COPD 1 2 1.000 
Myocardial infarction 17 18 0.746 
Etiology    
Ischemic 16 (73%) 24 0.119 
Nonischemic 6 (27%) 2  
Prior cardiac procedures   0.608 
None (%) 14 15  
PCI/PTCA (%) 6 6  
CABG (%) 2 5  
aCalculated as √[(height in cm*weight in kg)/3600] 
bCalculated as weight in kg/(height in m)2
 
 Information about the referring hospital and data relative to VAD implantation were also 
analyzed to determine if any of these factors might be predictive of a patient’s status at 30 days 
(see Table 6). None of these variables were shown to be significant predictors of 30-day survival. 
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Table 6 
Univariable Analysis of Implant and Referring Hospital for Short-term Survival  
 30 Days Post Implant  
Variable Survivors Nonsurvivors p 
Referral Hospital   0.385 
Small (0-200) 0 1  
Medium (201-500) 7 12  
Large (501+) 14 13  
Unknown 1 0  
Indication    
Cardiogenic Shock 16 21 0.732 
Postcardiotomyb 6 5  
Post-CABG 13 21 0.122 
Type of support   0.239 
Left (LVAD) only 11 7  
Right (RVAD) only 1 1  
Both (BiVAD) 10 18  
Days from Admission to Implant 1.5 +/- 1.77 2.54 +/- 2.56 0.116 
Days from Implant to Transfer 2.5 +/- 4.8 1.8 +/- 1.44 0.488 
 
 Clinical variables upon arrival were explored to determine if any were significant in a 
patient’s survival at 30 days post-implant (see Table 7). Only two variables were calculated as 
being significant. One was the requirement for vasoconstrictor medications (p= 0.039).  The 
other was the need for dialysis, specifically CVVH, within the first 24 hours at UMHS 
(p=0.006). 
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Table 7 
Univariable Analysis of Variables Indicating Clinical Status upon Arrival  
 30 Days Post Implant  
Variable Survivors Nonsurvivors p 
Vital Signs/Hemodynamics    
Heart Rate (bpm) 94 +/- 20 85.3 +/- 23 0.211 
Mean Systolic Blood Pressure 88 +/- 19 85 +/- 23 0.620 
Temperaturea (C)  37.2 +/- 1.1 37.2 +/- 0.6 0.884 
Pulmonary Artery Pressure 26.2 +/- 9.7 29.7 +/- 11.1 0.394 
Central Venous pressure 18.9 +/- 7.0 18.6 +/-8.8 0.924 
Cardiac output 4.66 +/- 0.7 5.03 +/- 1.4 0.297 
LVAD flow (L/min) 4.59 +/- 0.7 4.68 +/- 0.7 0.714 
RVAD flow  (L/min) 4.61 +/- 0.9 4.62 +/- 0.9 0.993 
Heart Rhythm   0.672 
Sinus 14 18  
Paced 3 5  
Atrial fibrillation 1 2  
Ventricular fibrillation 1 0  
Arterial Blood Gases    
O2 Saturation (%) 94.4 +/- 4.9 92.6 +/- 7.0 0.304 
pO2 129.9 +/- 72.6 154.8 +/- 135.6 0.445 
pCO2 37.0 +/- 6.0 37.0 +/- 8.7 0.896 
pH 7.42 +/- 0.1 7.40 +/- 0.1 0.497 
Ventricular Support    
Ventilator Rate  (breaths/min) 12.5 +/- 2.4 14.5 +/- 4.3 0.062 
PEEP  (cmH2O) 6.3 +/- 2.1 6.6 +/- 2.5 0.671 
Ventilator Mode   0.377 
AC 7 13  
IMV 13 13  
FiO2 (%) 85.5 +/- 22.6 89.2 +/- 19.0 0.532 
Intra-aortic Balloon Pump 3 9 0.095 
Medication requirements    
Inotropes 13 15 0.543 
Vasoconstrictors 7 18 0.039 
Vasodilators 6 6 0.734 
Chest tube output (mL)b 560 +/- 558 523 +/- 558 0.817 
Urine output (mL)b 1079 +/- 967 1289 +/- 1453 0.614 
Dialysis (CVVH)c 1 10 0.006 
aTmax over first 24 hours.  
bOver first 8 hours at UMHS. 
cWithin first 24 hours at UMHS. 
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 Values of laboratory blood tests were also tested in a univariable analysis, and the results 
are shown in Table 8. Univariate analysis showed that lower serum creatinine levels are 
significant (p=0.0001) in those that survive 30 days. Creatinine levels are used to determine 
kidney function, and a creatinine level of 0.7-1.3 mg/dL is considered normal. Two of the liver 
function tests were also shown to be significant by univariable analysis. AST (asparatate amino 
transferase) levels, which are often elevated in patients with cardiac disease, were significantly 
lower in survivors (p=0.041). The other significant test was LDH level (p=0.018), which is a 
measure of the amount of lactic dehydrogenase in the serum and an indicator of tissue damage. 
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Table 8 
Univariable Analysis of Laboratory Variables 
 30 Days Post Implant 
Variable Survivors Nonsurvivors p 
Chemistry Panel    
Sodium (mMOL/L) 139 +/- 5.6 142 +/- 6.8 0.195 
Potassium (mMOL/L) 4.1 +/- 0.7 4.4 +/- 0.9 0.170 
Chloride (mMOL/L) 108 +/- 6.6 108 +/- 5.3 0.939 
Bicarbonate (mMOL/L) 25.8 +/- 3.5 25.1 +/- 3.7 0.534 
Urea Nitrogen (mg/dL) 22.9 +/- 11.3 28.0 +/- 12.7 0.149 
Creatinine (mg/dL) 1.19 +/- 0.46 2.07 +/- 0.96 0.000 
Glucose (mg/dL) 130.6 +/- 40.0 157.9 +/- 65.1 0.094 
Calcium (mg/dL) 7.1 +/- 0.7 7.5 +/- 1.1 0.120 
Phosphorus (mg/dL) 4.5 +/- 1.6 4.5 +/- 2.8 0.962 
Protein – total (g/dL) 4.4 +/- 0.7 4.1 +/- 0.9 0.329 
Liver    
Albumin (g/dL) 2.11 +/- 0.4 2.07 +/- 0.6 0.782 
AST(IU/L) 503.7 +/-  602 1449.9 +/- 2027 0.041 
ALT (IU/L) 211 +/- 346 501+/- 810 0.126 
LDH (IU/L) 976 +/- 541 2635 +/- 2894 0.018 
Alkaline phosphatase (IU/L) 75.1 +/- 71.8 59.2 +/- 24.0 0.301 
Total Bilirubin (mg/dL) 1.61 +/- 1.8 2.74 +/- 2.8 0.110 
Hematology    
White Blood Cell Count (K/MM3) 11.4 +/- 3.9 12.1 +/- 5.7 0.593 
Hematocrit (%) 32.2 +/- 5.1 32.6 +/- 4.2 0.967 
Hemoglobin (g/dL) 11.1 +/- 1.7 11.2 +/- 1.4 0.873 
Platelet Count (K/MM3) 118.5 +/- 43.4 92.8 +/- 51.6 0.071 
Coagulation    
Prothrombin Time (sec) 12.9 +/- 3.1 18.0 +/- 17.9 0.193 
International Normalized Ratio 1.27 +/- 0.35 1.8 +/- 1.86 0.189 
Partial Thromboplastin Time (sec) 59.8 +/- 29.1 66.0 +/- 30.2 0.473 
 
Multivariate Analysis to Determine Prognostic Variables of 30-Day Survival 
 Multivariate analysis was performed using those variables that were significant in the 
univariate analysis for 30 day survival. These variables are shown in Table 9. Variables that 
remained significant were age (p=0.015) and creatinine levels (p=0.004).  
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Table 9 
Multivariable Analysis of Variables Identified in Univariable Analysis of 30-Day Survival 
 30 Days Post Implant  
Variable Survivors  (N=22) 
Nonsurvivors  
(N=26) p 
Demographics/Medical History    
Age 43+13 55+11 0.015 
Diabetes  2 (11%) 16 (53%) 0.087 
Other support    
Dialysis (CVVH) 1 (5%) 10 (38%) 0.350 
Vasoconstrictors 7 (32%) 18 (69%) 0.096 
Laboratory values    
Creatinine 1.2+0.5 2.1+1.0 0.004 
AST 503+601 1449+2027 0.510 
LDH 976+540 2635+2894 0.196 
 
Long-term Survival Based on Age and Serum Creatinine Levels 
 As previously shown, 54% of the patients transferred to UMHS with a temporary VAD 
did not survive 30 days after implant. Age and serum creatinine levels were shown to be 
significant prognostic variables of this survival based on multivariable analysis. Figure 4 shows a 
Kaplan-Meier analysis comparing patients who are younger or older than the median age of 50.9.  
 Statistical analysis reveals the survival of those younger than 50.9 to be significantly 
longer than those older than 50.9 (p=0.001).  
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Figure 4. Long-term survival dichotomized by median age  
 Creatinine levels were shown to be significant for 30-day survival. Kaplan-Meier analysis 
of the quartiles is shown in Figure 5. Patients with a creatinine level less than 1.0 mg/dl had an 
excellent chance of surviving not only 30 days after their implant, but also long term. None of 
the 13 patients with poor kidney function, as evidenced by their high creatinine levels (≥ 2.2 
mg/dl), survived past 30 days.  
 
At risk: 
Month: 0 1 12 24 48 72
< 50.9 24 17 16 14 7 5 
> 50.9 24 5 3 2 2 1 
Months
120 108 968472604836 24 12 0 
 
1.0 
0.8 
0.6 
0.4 
0.2 
0.0 P=0.001 by log rank 
Age > 50.9 
Age < 50.9 
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Figure 5. Long-term survival of patients based on serum creatinine levels (grouped by quartiles)  
Patient Outcomes 
 Twenty patients in this study died while still on short-term mechanical support after 
being transferred to UMHS for further care. The six remaining patients who did not survive 30 
days were either weaned (N=3) or received a more permanent VAD (N=3) but ultimately died 
from complications of their heart failure. A flowchart of all patient outcomes is shown in Figure 
6.    
At risk: 
Month: 0 1 12 24 48 72
< 1.0 mg/dl 9 7 5 5 2 2 
< 1.4 mg/dl 14 8 8 6 4 2 
< 2.2 mg/dl 12 7 6 5 3 2 
≥ 2.2 mg/dl 10 0 0 0 0 0 
Months
120 108 968472604836 24 12 0 
 
1.0 
0.8 
0.6 
0.4 
0.2 
0.0 
Cr < 1.0 mg/dl 
Cr < 1.4 mg/dl 
Cr < 2.2 mg/dl 
Cr ≥ 2.2 mg/dl 
P=0.0001 by log rank
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Figure 6. Patient outcomes (as of 09/17/2007) 
 Of the 22 patients who survived past 30 days post-implant, 16 went on to receive a long-
term VAD. Thirteen of the survivors ultimately received a heart transplant, and 10 of the 
transplant recipients are still alive.  
 Further analysis of current survival revealed that most have lived past one year (see 
Figure 7).  In addition, 82% (n=18) of those surviving 30 days post-implant are currently alive 
with the potential of living greater than 5 years and perhaps more. 
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Figure 7. Current survival past implant of those surviving >30 days post-implant 
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CHAPTER 5: Discussion 
 Heart failure, either chronic from an underlying cardiovascular disease, or acute, such as 
failure to wean from cardiopulmonary bypass after heart surgery or cardiogenic shock from an 
MI, can cause sudden death if not treated immediately. Unfortunately, many people are not near 
a hospital when treatment is required and even fewer are near a tertiary cardiac center, where 
more options are available to them. This study was designed to examine those patients who 
received a short-term VAD for treatment of their heart failure at a hospital other than UMHS and 
were subsequently transferred to UMHS for further treatment. 
 The majority of patients in this study were Caucasian males with a median age of 50.9 
years, a history of hypertension, myocardial infarction, and ischemic heart disease. Implantation 
of a short-term device was required due to postcardiotomy after CABG surgery and required 
biventricular support. Upon transfer to UMHS, more than half of them required inotrope therapy 
and vasoconstrictors, while less than one fourth required dialysis. 
 This is similar to the experiences of Gonzalez-Stawinski et al. (2006) at the Cleveland 
Clinic Foundation, in which their median age was 51 years and 85% required a temporary VAD 
for postcardiotomy. They did report a much smaller percentage with ischemic disease (46%) as 
compared to this analysis.  
 Kaplan-Meier analysis of the UMHS patients in this study showed that just over half died 
within the first 30 days after implantation of their short-term device. Gonzalez-Stawinski et al. 
(2006) reported their survival rate was 38%, and Morris et al. reported a survival rate of 32%.  
Separate centers are likely to have differing experiences, and results cannot necessarily be 
considered comparable. In addition, long-term treatments for heart failure are constantly 
improving, and the treatment given by the referring centers may impact the survival rate.   
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 Identification of prognostic variables for short-term survival revealed age and kidney 
function, as shown by creatinine levels, as significant. Younger patients presenting to UMHS 
with better kidney function were more likely to survive 30 days post-implant. These patients 
were also most likely to be eligible for heart transplantation, thereby increasing the likelihood of 
long-term survival. Gonzalez-Stawinski et al. (2006) also reported that younger age, less 
complex surgery, and organ function were significant factors in their survival analysis.  
 Previous studies did not examine survival past one year. Patients in this study were very 
likely to live more than 5 years after implant if they survived the initial 30 days. The majority of 
them received a heart transplant during that time, most likely due to the fact that their younger 
age and better kidney function presented them as good candidates for transplant. 
 Experience at UMHS is consistent with these other reports that have shown that hub and 
spoke referral systems increase survival. 
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CHAPTER 6: Limitations 
This study is a single center’s experience on patients transferred with a short-term VAD 
for cardiogenic support. This study does have the limitations of being a retrospective. Some data 
elements were found to be missing or incomplete. In addition, this was a small study population, 
and some variables may truly be significant when examined in a larger population. 
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CHAPTER 7: Conclusion 
 Patients that go into cardiogenic shock are often treated by implantation of a temporary 
VAD at a community hospital. Once implanted, these patients will often be transferred to a 
tertiary care center for further treatment as part of a “hub and spoke” referral system. 
Identification of prognostic variables significant in survival of these patients could affect 
patient care decisions at both the referring and receiving hospital. The experience of previous 
patients transferred to the University of Michigan Health System with a temporary VAD for 
cardiogenic shock identified two variables that were indicative of survival. Patients who 
survived 30 days post-implant were generally younger and had better kidney function as 
measured by serum creatinine. The majority of the surviving patients eventually received a 
heart transplant, most likely because their younger age and better kidney function greatly 
improved their chances of being a transplant candidate and possibly increased their chances 
of survival after transplant.  
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